These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28378895)

  • 1. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
    Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
    Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.
    Khoy K; Mariotte D; Defer G; Petit G; Toutirais O; Le Mauff B
    Front Immunol; 2020; 11():549842. PubMed ID: 33072089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
    J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.
    Granell-Geli J; Izquierdo-Gracia C; Sellés-Rius A; Teniente-Serra A; Presas-Rodríguez S; Mansilla MJ; Brieva L; Sotoca J; Mañé-Martínez MA; Moral E; Bragado I; Goelz S; Martínez-Cáceres E; Ramo-Tello C
    J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended interval dosing of natalizumab in multiple sclerosis.
    Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.
    Vitaliti G; Matin N; Tabatabaie O; Di Traglia M; Pavone P; Lubrano R; Falsaperla R
    Expert Rev Neurother; 2015; 15(11):1321-41. PubMed ID: 26513633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
    Benkert TF; Dietz L; Hartmann EM; Leich E; Rosenwald A; Serfling E; Buttmann M; Berberich-Siebelt F
    PLoS One; 2012; 7(12):e52208. PubMed ID: 23284936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing.
    Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR
    Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    van Kempen ZLE; Hoogervorst ELJ; Wattjes MP; Kalkers NF; Mostert JP; Lissenberg-Witte BI; de Vries A; Ten Brinke A; van Oosten BW; Barkhof F; Teunissen CE; Uitdehaag BMJ; Rispens T; Killestein J
    Neurology; 2020 Aug; 95(6):e745-e754. PubMed ID: 32690785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.
    Hunt D; Giovannoni G
    Pract Neurol; 2012 Feb; 12(1):25-35. PubMed ID: 22258169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
    Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
    Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of natalizumab in multiple sclerosis: current perspectives.
    Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Toorop AA; van Lierop ZY; Gelissen LM; Hoitsma E; Zeinstra EM; van Rooij LC; van Munster CE; Vennegoor A; Mostert JP; Wokke BH; Kalkers NF; Hoogervorst EL; van Eijk JJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige L; Kloosterziel ME; Arnoldus EP; van Dijk GW; Bouvy WH; Wessels MH; Boonkamp L; Strijbis EM; van Oosten BW; De Jong BA; Lissenberg-Witte BI; Barkhof F; Moraal B; Teunissen CE; Rispens T; Uitdehaag BM; Killestein J; van Kempen ZL
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):392-400. PubMed ID: 37963723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A; Stüve O
    J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.
    Jing D; Oelschlaegel U; Ordemann R; Hölig K; Ehninger G; Reichmann H; Ziemssen T; Bornhäuser M
    Bone Marrow Transplant; 2010 Oct; 45(10):1489-96. PubMed ID: 20098455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab in aggressive multiple sclerosis after haematopoietic stem cell transplantation.
    Capobianco M; Motuzova Y; Frau J; Cocco E; Mamusa E; Marrosu MG; Bertolotto A
    Neurol Sci; 2012 Aug; 33(4):863-7. PubMed ID: 22116203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis.
    O'Leary S; Brugger HT; Wallentine D; Sershon L; Goff E; Saldana-King T; Beavin J; Avila RL; Rutledge D; Moore M
    J Infus Nurs; 2023 Nov-Dec 01; 46(6):347-359. PubMed ID: 37920108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.